Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 28, Issue 2, 2001, Pages 150-153

  Kunches, Laureen M ^a,d   Reinhalter, Nancy E ^a   Marquis, Ayodeji ^a   Coakley, Eugenie ^a   Cohen, Calvin ^b,c   Morris, Anne B ^b,c   Mazzullo, John M ^a  

^a JSI Inc   (United States)

^b Community Research Initiative of New England ^*  (United States)

^c 44 Farnsworth St ^*  (United States)

^d JOHN SNOW INC   (United States)

Author keywords

Antiretrovirals; ddI; Didanosine; HIV infection; Side effects; Tolerability

Indexed keywords

DIDANOSINE;

ABDOMINAL CRAMP; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DRUG CAPSULE; DRUG FORMULATION; DRUG TOLERABILITY; ENTERIC COATED TABLET; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE; NAUSEA; PALATABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ADULT; AMYLASES; ANTI-HIV AGENTS; BOSTON; CAPSULES; CD4 LYMPHOCYTE COUNT; CROSS-OVER STUDIES; DIARRHEA; DIDANOSINE; DRUG TOLERANCE; FEMALE; HIV INFECTIONS; HUMANS; MALE; NAUSEA; PATIENT SELECTION; TABLETS;

EID: 0035477717     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200110010-00006     Document Type: Article

References (10)

1. Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: Results of a phase I trial
2. Didanosine in the treatment of AIDS and AIDS-related complex: A critical appraisal of the dose and frequency of administration
3. Patient appraisal of mandarin orange didanosine: Implications for adherence and wellbeing
4. GSRS: A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease
5. Improved tolerability and adherence with reduced mass didanosine tablets in HIV-1 infected adults receiving highly active antiretroviral therapy
6. Bioequivalence of two formulations of didanosine (ddI), enteric coated and the chewable tablet, in healthy volunteers and subjects infected with HIV
7. Lack of effect of didanosine encapsulated enteric coated beadlet formulation on the pharmacokinetics of indinavir, ketoconazole, and ciprofloxacin in healthy subjects
8. Comparison of a triple combination regimen containing an enteric-coated formulation of didanosine administered once daily versus a regimen of Combivir plus nelfinavir
9. Comparison of HIV RNA suppression produced by triple regimens containing either didanosine enteric-coated or didanosine tablet formulations each administered once daily